GlassScriptPhysician profile
Marta Dworakowski
NPI 1700543279
$8,597.58
in general payments reported to CMS, 2019-2025
25 companies · $75.50 in 2025
The $75.50 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.82 · 2022: $1,528 · 2023: $4,939 · 2024: $2,040 · 2025: $75.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,634 · Travel and Lodging: $2,289 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,634.00 |
| Travel and Lodging | $2,289.16 |
| Education | $131.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $2,947.76 | 2022-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Pascal |
| Boston Scientific Corporation | $2,913.70 | 2022-2025 | Watchman Access System, Watchman, Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $820.46 | 2022-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $257.80 | 2023-2024 | Verquvo |
| Alnylam Pharmaceuticals INC. | $210.94 | 2023 | Amvuttra, Onpattro |
| Astrazeneca Pharmaceuticals LP | $184.08 | 2022-2024 | Wainua, Farxiga |
| Novartis Pharmaceuticals Corporation | $165.48 | 2022-2024 | |
| Abbott Laboratories | $149.08 | 2022 | |
| Janssen Pharmaceuticals, INC | $129.53 | 2022-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $123.95 | 2023-2024 | Lifevest |
| Amgen INC. | $110.03 | 2022-2024 | Repatha |
| Abiomed | $105.96 | 2023 | Impella |
| Biotronik INC. | $79.55 | 2022 | |
| Pfizer INC. | $50.34 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $48.57 | 2024 | Eliquis |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $46.71 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Sanofi-Aventis U.S. LLC | $37.68 | 2023 | |
| Scpharmaceuticals INC. | $37.08 | 2023 | |
| Chiesi USA, INC. | $31.76 | 2023 | Cleviprex, Kengreal |
| Medtronic, INC. | $30.09 | 2021-2023 | Corevalve Evolut R |
| Esperion Therapeutics, INC. | $30.07 | 2024 | Nexletol |
| Inspire Medical Systems, INC. | $22.71 | 2023 | Inspire |
| Lexicon Pharmaceuticals, INC. | $22.42 | 2023 | Inpefa |
| Kiniksa Pharmaceuticals, LTD. | $21.11 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $20.72 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marta Dworakowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.